Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-action, filing
TL;DR
Processa Pharma filed an 8-K on 9/11/25 for shareholder votes & financials.
AI Summary
On September 11, 2025, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a submission of matters to a vote of security holders and includes financial statements and exhibits. The company, formerly known as Heatwurx, Inc., is incorporated in Delaware and headquartered in Vero Beach, Florida.
Why It Matters
This 8-K filing signals that Processa Pharmaceuticals, Inc. is engaging in corporate actions requiring shareholder votes and is providing updated financial information, which could impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediate negative news or significant financial events.
Key Numbers
- 001-39531 — Commission File Number (Identifies the company's filing with the SEC)
- 45-1539785 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Heatwurx, Inc. (company) — Former company name
- September 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Vero Beach, FL (location) — Address of Principal Executive Offices
FAQ
What specific matters are being submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What are the key financial statements and exhibits included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these documents is not detailed in the provided text.
When was Processa Pharmaceuticals, Inc. formerly known as Heatwurx, Inc. and when did the name change occur?
The company was formerly known as Heatwurx, Inc., and the date of the name change was October 28, 2011.
What is the principal executive office address for Processa Pharmaceuticals, Inc.?
The principal executive offices are located at 601 21st Street, Suite 300, Vero Beach, FL 32960.
What is the telephone number for Processa Pharmaceuticals, Inc.?
The registrant's telephone number, including area code, is (772) 453-2899.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2025-09-11 19:45:21
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PCSA Nasdaq Ca
Filing Documents
- form8-k.htm (8-K) — 50KB
- 0001493152-25-013108.txt ( ) — 214KB
- pcsa-20250911.xsd (EX-101.SCH) — 3KB
- pcsa-20250911_lab.xml (EX-101.LAB) — 33KB
- pcsa-20250911_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 11, 2025, the Company held a Special Meeting of Shareholders (the "Special Meeting"). A total of 50,349,149 shares of common stock were entitled to vote as of August 7, 2025, the record date for the Special Meeting. Present at the Special Meeting in person or by proxy were holders of 17,127,838 shares of common stock of the Company, representing at least one-third (1/3) of the voting power of the common stock of the Company outstanding and entitled to vote, constituting a quorum for the transaction of business. The shareholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the shareholders and the final voting results of each such proposal. 1. Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 1,000,000,000 (the "Charter Proposal"): Shares For Against Abstain 13,706,276 3,029,091 392,471 2. Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, to effect a reverse stock split of the Company's outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-2 and not more than 1-for-50, such ratio to be determined in the sole discretion of the Company's Board of Directors, without a corresponding reduction in the Company's authorized shares, and to be effective upon a date determined by the Board of Directors no later than December 31, 2026 (the "Reverse Stock Split Proposal"): Shares For Against Abstain 13,887,533 3,126,720 113,585 3. Approval of an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the Plan (the "OIP Pr
01(d) Financial Statements and Exhibits
Item 9.01(d) Financial Statements and Exhibits 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROCESSA PHARMACEUTICALS, INC. Date: September 12, 2025 By: /s/ Russell Skibsted Russell Skibsted Chief Financial Officer